Exact Sciences Corporation
$4.4M 107,493 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Salix Pharmaceuticals, a division of Bausch Health US, LLC
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported $4,399,798.16 across General Payments, Research, and Ownership to 161,040 physicians and teaching hospitals across 161,040 transactions.
- $4.4M
- All-tracks total
- 161,040
- Transactions
- 161,040
- Recipients
- −$740.1K
- General Payments vs PY2023
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported $4,399,798.16 across all CMS Open Payments tracks (General + Research + Ownership) to 161,040 physicians and teaching hospitals in Program Year 2024 - ranking #293 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $4,399,798.16, averaging $27.32 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer salix-pharmaceuticals-a-division-of-bausch-health-us-llc Salix Pharmaceuticals, a division of Bausch Health US, LLC
$4.4M · #293/1,925 · 0.0% industry · PY2024
- TOT $4.4M
- RANK #293
- SHARE 0.0%
- TXN 161,040
- RCP 161,040
- CAT 7
- GEN $4.4M
- ΔGEN −$740.1K
- TOP1 2.1%
- PY 2024
Volume peers
Nearest volume peer: Exact Sciences Corporation ($4.4M)
Salix Pharmaceuticals, a division of Bausch Health US, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Salix Pharmaceuticals, a division of Bausch Health US, LLC's CMS-reported General Payments decreased by $740.1K (−14.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SALIX PHARMACEUTICALS, A DIVISION OF BAUSCH HEALTH US, LLCPY2023: SALIX PHARMACEUTICALS, A DIVISION OF BAUSCH HEALTH US, LLCPY2024: Salix Pharmaceuticals, a division of Bausch Health US, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $5,139,901.38
- PY2024
- $4,399,798.16
What the Data Shows for Salix Pharmaceuticals, a division of Bausch Health US, LLC
Salix Pharmaceuticals, a division of Bausch Health US, LLC ranks #293 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $4,399,798.16 across 161,040 transactions to 161,040 physicians and teaching hospitals - $27.32 per transaction and $27.32 per recipient on average.
The 7-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $2.8M, accounting for 64.4% of this company's General Payments and 160,083 transactions.
General Payment Breakdown by Type
Across 7 types of general payments, Salix Pharmaceuticals, a division of Bausch Health US, LLC's largest category was "Food and Beverage" at $2.8M - 64.4% of General Payments.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reports 7 general-payment categories - the top three are Food and Beverage (64.4%), Compensation for Faculty or Speaker (Medical Education) (19.6%), and Consulting Fee (8.8%). The remaining 4 categories make up 7.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Salix Pharmaceuticals, a division of Bausch Health US, LLC divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $2.8M | 160,083 | 64.4% |
| Compensation for Faculty or Speaker (Medical Education) | $862.8K | 259 | 19.6% |
| Consulting Fee | $386.6K | 75 | 8.8% |
| Travel and Lodging | $145.2K | 556 | 3.3% |
| Compensation for Services Other Than Consulting | $94.1K | 38 | 2.1% |
| Grant | $76.7K | 12 | 1.7% |
| Education | $201.89 | 17 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $409,119.06 (9.3%) of $4,399,798.16 in this company's General Payments records across 42,072 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Salix Pharmaceuticals, a division of Bausch Health US, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Eileen M Almon
$91,920.00 across 4 reported transactions
- 2
Conar Fitton
$88,563.37 across 120 reported transactions
- 3
Arun Jesudian
$82,886.63 across 95 reported transactions
- 4
Apurva Modi
$76,809.06 across 100 reported transactions
- 5
Kristen Marie Lervik
$68,940.00 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Salix Pharmaceuticals, a division of Bausch Health US, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Salix Pharmaceuticals, a division of Bausch Health US, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Salix Pharmaceuticals, a division of Bausch Health US, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Octapharma USA, Inc.
$4.4M 5,207 recipients
Compare payment profiles
Bolton Medical Inc
$4.4M 4,442 recipients
Compare payment profiles
Novocure Inc.
$4.5M 3,615 recipients
Compare payment profiles
bluebird bio, Inc.
$4.5M 229 recipients
Compare payment profiles
Kerecis Limited
$4.3M 26,463 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.